Edwards Lifesciences reports Q2 adjusted EPS 67c, consensus 62c

Reports Q2 revenue $1.53B, consensus $1.49B. “We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,” said Bernard Zovighian, CEO. “Edwards is increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come as we help even more patients around the world.”